Back

Prognostic factors associated with survival in patients with wild-type transthyretin amyloid cardiomyopathy, treated with tafamidis

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - epidemiology, prognosis, outcome 3 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Assistant Professor Gregor Zemljic

University Medical Centre Ljubljana, Ljubljana (Slovenia)

7 More presentations in this session

Presentation thumbnail
Prevalence, outcomes and the correlates of stress induced hyperglycemia among patients admitted for acute heart failure
Doctor D. Mabula (Mwanza, TZ)
Abstract Slides Video
Presentation thumbnail
Lenght of stay in patients with acutely decompensated heart failure with reduced ejection fraction - associated factors and predictors
Doctor J. Stevic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Impact of BNP levels as predictors of prognosis in heart failure patients with ARNI
Doctor D. maebuchi (kuki, JP)
Abstract Slides Video
Presentation thumbnail
Impact of optimized therapy on the evolution of patients with heart failure - reality of an advanced heart failure outpatient clinic of the unified health system
Doctor G. Assink De Castro (Curitiba, BR)
Abstract Slides Video
Presentation thumbnail
Are patients with de novo and chronic heart failure with reduced ejection fraction different? Results of a contemporary registry.
Doctor J. Bonilla Palomas (Ubeda, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - epidemiology, prognosis, outcome 3

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Prognostic value of heart failure hospitalization in transthyretin cardiac amyloidosis: an international cohort study
thumbnail
Congress Presentation
Atrial fibrillation is associated with worse outcome in patients with wild-type transthyretin amyloid cardiomyopathy
thumbnail
Congress Presentation
Beyond stability: unveiling the prognostic and therapeutic role of serum transthyretin in amyloid cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources